Literature DB >> 17520250

Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease.

Miharu Samuraki1, Ichiro Matsunari, Wei-Ping Chen, Kazuyoshi Yajima, Daisuke Yanase, Akihiko Fujikawa, Nozomi Takeda, Shintaro Nishimura, Hiroshi Matsuda, Masahito Yamada.   

Abstract

PURPOSE: Although( 18)F-fluorodeoxyglucose (FDG) PET is an established imaging technique to assess brain glucose utilisation, accurate measurement of tracer concentration is confounded by the presence of partial volume effect (PVE) due to the limited spatial resolution of PET, which is particularly true in atrophic brains such as those encountered in patients with Alzheimer's disease (AD). Our aim was to investigate the effects of PVE correction on FDG PET in conjunction with voxel-based morphometry (VBM) in patients with mild AD.
METHODS: Thirty-nine AD patients and 73 controls underwent FDG PET and MRI. The PVE-corrected grey matter PET images were obtained using an MRI-based three-compartment method. Additionally, the results of PET were compared with grey matter loss detected by VBM.
RESULTS: Before PVE correction, reduced FDG uptake was observed in posterior cingulate gyri (PCG) and parieto-temporal lobes (PTL) in AD patients, which persisted after PVE correction. Notably, PVE correction revealed relatively preserved FDG uptake in hippocampal areas, despite the grey matter loss in medial temporal lobe (MTL) revealed by VBM.
CONCLUSION: FDG uptake in PCG and PTL is reduced in AD regardless of whether or not PVE correction is applied, supporting the notion that the reduced FDG uptake in these areas is not the result of atrophy. Furthermore, FDG uptake by grey matter tissue in the MTL, including hippocampal areas, is relatively preserved, suggesting that compensatory mechanisms may play a role in patients with mild AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17520250     DOI: 10.1007/s00259-007-0454-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  44 in total

1.  Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

Authors:  K Herholz; E Salmon; D Perani; J C Baron; V Holthoff; L Frölich; P Schönknecht; K Ito; R Mielke; E Kalbe; G Zündorf; X Delbeuck; O Pelati; D Anchisi; F Fazio; N Kerrouche; B Desgranges; F Eustache; B Beuthien-Baumann; C Menzel; J Schröder; T Kato; Y Arahata; M Henze; W D Heiss
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

2.  Correction for partial-volume effects on brain perfusion SPECT in healthy men.

Authors:  Hiroshi Matsuda; Takashi Ohnishi; Takashi Asada; Zhi-jie Li; Hidekazu Kanetaka; Etsuko Imabayashi; Fumiko Tanaka; Seigo Nakano
Journal:  J Nucl Med       Date:  2003-08       Impact factor: 10.057

Review 3.  Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI.

Authors:  M Jueptner; C Weiller
Journal:  Neuroimage       Date:  1995-06       Impact factor: 6.556

4.  Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies.

Authors:  Kazunari Ishii; Hiroki Sasaki; Atsushi K Kono; Naokazu Miyamoto; Tetsuya Fukuda; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-31       Impact factor: 9.236

5.  Statistical parametric mapping of (99m)Tc-HMPAO-SPECT images for the diagnosis of Alzheimer's disease: normalizing to cerebellar tracer uptake.

Authors:  Darius Soonawala; Tania Amin; Klaus P Ebmeier; J Douglas Steele; Nadine J Dougall; Jonathan Best; Octave Migneco; Flavio Nobili; Klemens Scheidhauer
Journal:  Neuroimage       Date:  2002-11       Impact factor: 6.556

6.  A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease.

Authors:  C A Davies; D M Mann; P Q Sumpter; P O Yates
Journal:  J Neurol Sci       Date:  1987-04       Impact factor: 3.181

Review 7.  The role of imaging in the pathophysiology and diagnosis of headache.

Authors:  Arne May
Journal:  Curr Opin Neurol       Date:  2005-06       Impact factor: 5.710

8.  Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease.

Authors:  V Ibáñez; P Pietrini; G E Alexander; M L Furey; D Teichberg; J C Rajapakse; S I Rapoport; M B Schapiro; B Horwitz
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

9.  Altered glucose metabolism in the hippocampal head in memory impairment.

Authors:  Y Ouchi; S Nobezawa; H Okada; E Yoshikawa; M Futatsubashi; M Kaneko
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

10.  Plasticity of hippocampal circuitry in Alzheimer's disease.

Authors:  J W Geddes; D T Monaghan; C W Cotman; I T Lott; R C Kim; H C Chui
Journal:  Science       Date:  1985-12-06       Impact factor: 47.728

View more
  32 in total

1.  Age-related metabolic profiles in cognitively healthy elders: results from a voxel-based [18F]fluorodeoxyglucose-positron-emission tomography study with partial volume effects correction.

Authors:  P K Curiati; J H Tamashiro-Duran; F L S Duran; C A Buchpiguel; P Squarzoni; D C Romano; H Vallada; P R Menezes; M Scazufca; G F Busatto; T C T F Alves
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-27       Impact factor: 3.825

Review 2.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

Review 3.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

4.  'Intensity diffusion' is a better description than 'partial volume effect'.

Authors:  Arne Skretting
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-21       Impact factor: 9.236

Review 5.  Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.

Authors:  Abhay P Sagare; Robert D Bell; Berislav V Zlokovic
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

Review 6.  Imaging approaches for dementia.

Authors:  A D Murray
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-01       Impact factor: 3.825

7.  Role of structural MRI in Alzheimer's disease.

Authors:  Prashanthi Vemuri; Clifford R Jack
Journal:  Alzheimers Res Ther       Date:  2010-08-31       Impact factor: 6.982

Review 8.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

9.  Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data.

Authors:  Douglas N Greve; Claus Svarer; Patrick M Fisher; Ling Feng; Adam E Hansen; William Baare; Bruce Rosen; Bruce Fischl; Gitte M Knudsen
Journal:  Neuroimage       Date:  2013-12-19       Impact factor: 6.556

Review 10.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.